We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Hikma Pharmaceuticals plc (PK) | USOTC:HKMPY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.87 | -1.69% | 50.66 | 49.63 | 51.63 | 52.10 | 50.65 | 52.10 | 1,516 | 21:01:21 |
From Jun 2019 to Jun 2024
LONDON--Hikma Pharmaceuticals PLC (HIK.LN) said Monday it has signed an exclusive licensing and distribution agreement with Finnish pharmaceutical company Orion Corporation, for Orion's new Easyhaler combination product, a dry powder inhaler, for the treatment of asthma and chronic obstructive pulmonary disease.
The agreement gives Hikma the exclusive rights to register, distribute, market and sell the product in all of its Middle East and North Africa or MENA markets.
Hikma shares at 0925 GMT up 14 pence, or 0.7%, at GBP19.51, valuing the company at GBP4.68 billion.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
February 13, 2017 04:43 ET (09:43 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Hikma Pharmaceuticals (PK) Chart |
1 Month Hikma Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
